UPDATE 1-Kailera's weight-loss drug meets main goal of late-stage trials in China

Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc.

KLRA

0.00

Adds details in paragraphs 2 to 4

July 7 (Reuters) - Kailera Therapeutics KLRA.O said on Tuesday its oral obesity and diabetes drug met the main goal of two late-stage trials conducted in China.

The studies were conducted by its China-based partner Hengrui Pharma 600276.SS.

In the obesity trial, the drug, HRS-7535, achieved a mean weight loss of up to 10.9% at week 44 and a mean weight loss of up to 11.1% at week 50.

Kailera is also advancing the drug in a global mid-stage clinical trial in people living with obesity or overweight. The trial was initiated in April 2026, with data expected in 2027.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.